Website to teach people how to prevent liver cancer
Official title: Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention
Run by M.D. Anderson Cancer Center · NCT07010315 · Data updated 2026-11-12
This project will test a website that teaches adults at risk about liver cancer prevention and lets them get a personal risk summary.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | May 1, 2025 |
| Main results expected | April 30, 2027 |
| Study ends | April 30, 2027 |
| Registry record updated | August 6, 2026 |
| Trial ID | NCT07010315 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (18+) who receive care at the HOPE Clinic, can read English or Spanish, are not diagnosed with liver cancer, and (for usability testing) can navigate websites on a smartphone or study computer.
✕Probably not a fit
People already diagnosed with liver cancer, those who cannot provide consent or have vision/hearing impairments that prevent participation, and individuals who do not read English or Spanish are unlikely to benefit from this tool.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will develop and refine a web-based, patient-facing educational tool about liver cancer prevention using iterative cognitive and usability testing. Adults (18+) who receive care at the HOPE Clinic and speak English or Spanish will complete cognitive interviews to check comprehension and usability sessions to practice entering risk factors on a phone or study computer. Study staff will revise text, messages, layout, and functionality until interviewer notes show participants understand the content and can independently input risk factors and download a personal summary. Acceptability will be measured with the Ottawa Acceptability Measures and knowledge with study-designed questions to describe user response and learning.
Why it matters
Potential benefit: If successful, the tool could help patients better understand their liver cancer risk and take preventive actions or seek appropriate care earlier.
How similar studies have gone: Similar web-based educational and usability-focused interventions for cancer prevention have generally improved user knowledge and ease of use, but this specific liver cancer prevention tool is a novel, targeted effort.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least 18 years old * Participants at the HOPE Clinic * Able to speak and read either English or Spanish * For usability testing: Able to use and navigate websites on own smart phone or study computer Exclusion Criteria: * Has been diagnosed with liver cancer * Cannot provide consent or otherwise participate in research activities (e.g. vision or hearing impairment)
Where it's running
-
MD Anderson Cancer Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Jessica Hwang, MD, MPH — M.D. Anderson Cancer Center
- Study coordinator: Jessica Hwang, MD, MPH
- Email: jphwang@mdanderson.org
- Phone: (346) 720-7352
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer
This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.
-
Protoacoustic Imaging to See Radiation Delivery in Proton Therapy
This study tests radioacoustic imaging with ultrasound to help doctors see where proton therapy is delivering radiation for liver and prostate cancer patients.
-
YMN-136 vaccine for advanced liver, biliary tract, and pancreatic cancers
A first-in-human dose-escalation study tests whether the YMN-136 vaccine is safe and tolerable for adults with unresectable advanced liver, biliary tract, or pancreatic cancers who have progressed on standard therapies or cannot receive them.
-
DRAGON: International registry for patients who had combined portal and hepatic vein embolization before liver surgery
This registry collects data on patients who had PVE/HVE before liver resection to see if it helps liver regeneration and what factors relate to outcomes.
-
Precision navigation to boost cancer screening participation in high-risk communities
This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.